PHILADELPHIA (MedPage Today) -- Antibiotic resistance is a growing problem in modern medicine, but few new antimicrobial drugs are coming down the pipeline -- for both economic and regulatory reasons, as experts discuss in this InFocus™ segment.
regulatory reasons |
